Follow-up Care After Biopsy

Introduction to Follow-up Care

The British Journal of Dermatology recommends review at 3 months after initial consultation, then 6 months later for children, and follow-up at 3 months after diagnosis and initial treatment with topical steroid, then 6 months later if good response for adults (male) 1
The British Journal of Dermatology also recommends review after surgery to assess residual disease post-circumcision 1

The National Comprehensive Cancer Network recommends follow-up cystoscopy at 3-month intervals for non-muscle invasive disease after TURBT, and selected mapping biopsies, TUR of prostate, evaluation of upper tract for positive cytology with negative cystoscopy 2, 3
The Journal of Urology recommends annual chest X-ray for 5 years for low-risk RCC, oncocytoma, or non-diagnostic biopsies after ablative procedures, and no further radiological scanning if treatment success confirmed for benign confirmed histology 4
The Journal of Urology also recommends repeat biopsy if radiographic evidence of failure within 6 months for treatment failure 4

European Urology recommends follow-up with serial PSA (at least every 6 months), DRE, and MRI (at least once yearly), with standard repeat biopsy for active surveillance, and may omit repeat biopsy if stable disease and low PSA density (<0.15) for negative MRI during surveillance 5
The Journal of Urology recommends repeat biopsy for progressive changes, such as a progressive increase in size of an ablated neoplasm, new nodularity, or failure of a treated lesion to regress 4

The National Comprehensive Cancer Network and European Urology guidelines emphasize the importance of individualized follow-up care based on cancer type, stage, and risk factors, as well as patient age, gender, and lesion location 2, 3, 5
The National Comprehensive Cancer Network recommends that the surveillance schedule for a biopsied skin lesion depends on the histopathologic diagnosis, with melanoma requiring more frequent follow-up than benign lesions 6, 7
The following follow-up schedules are recommended by the National Comprehensive Cancer Network and the American Academy of Dermatology:
For benign lesions, the National Comprehensive Cancer Network recommends:
Special considerations:
Patient education:
Surveillance intervals should be tailored to the individual's risk factors (skin type, family history, presence of dysplastic nevi) 10
The National Comprehensive Cancer Network notes that most melanoma recurrences occur within the first 5 years, but late recurrence (≥10 years) is well documented, and the lifetime risk of developing a second primary melanoma is 4-8%, justifying lifelong dermatologic surveillance 10